Christopher M. Starr

All filings by Christopher M. Starr on record concern Monopar Therapeutics, in the capacity of board member. Over a trading history stretching from 30 June 2021 to 1 October 2026, the count stands at 16 filings.

Sales make up the whole of the open-market record (3 sales, €582k). Other entries cover 1 share grant and 12 option exercises. So far in 2026, the count stands at no purchases and 3 sales.

On 5 October 2026 came the latest disclosure, an option exercise for €37 in Monopar Therapeutics. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.